Julian S Rechberger1, Victor M Lu2, Liang Zhang1, Erica A Power1,3, David J Daniels4. 1. Department of Neurologic Surgery, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA. 2. Department of Neurologic Surgery, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA. lu.victor@mayo.edu. 3. Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, MN, USA. 4. Department of Neurologic Surgery, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA. daniels.david@mayo.edu.
Abstract
PURPOSE: Diffuse intrinsic pontine glioma (DIPG) is a lethal high-grade pediatric brainstem tumor without a cure. Despite numerous clinical trials over the last decades, the prognosis has remained poor. The aim of this update was to report on the status and outcomes of all clinical trials for DIPG performed to better understand the landscape of research efforts for this diagnosis to date. METHODS: The ClinicalTrials.gov database was reviewed in May 2019 for all possible interventional clinical trials that included DIPG as a diagnosis of primary investigation. These were then screened against selection criteria to identify pertinent clinical trials. RESULTS: Ninety-five clinical trials satisfied all inclusion criteria, with 55 (58%) trials specific to the DIPG diagnosis only. In terms of the most prevalent design features, 42 (44%) were phase I trials, with median expected start and completion years in 2011 (range, 1994-2020) and 2018 (range, 2005-2047), respectively. Median target number of patients to enroll was 38 (range, 1-1500), and the most common primary outcome was safety and toxicity (56%). There were 69 (73%) trials originating from the USA, with 49 (52%) of them being single institutional. Only 10 (11%) trials have reported results to date. CONCLUSIONS: To date, 95 clinical trials investigating DIPG with specific emphasis have been registered on ClinicalTrials.gov. There were only a small number of trials that had study results available, and they uniformly reported non-significant improvement to prognosis. Given the rarity and lethality of DIPG, which limits the accumulation of large cohorts, our results mandate the need for more robust, systematic clinical trial design to minimize redundancies and maximize yield in the future.
PURPOSE: Diffuse intrinsic pontine glioma (DIPG) is a lethal high-grade pediatric brainstem tumor without a cure. Despite numerous clinical trials over the last decades, the prognosis has remained poor. The aim of this update was to report on the status and outcomes of all clinical trials for DIPG performed to better understand the landscape of research efforts for this diagnosis to date. METHODS: The ClinicalTrials.gov database was reviewed in May 2019 for all possible interventional clinical trials that included DIPG as a diagnosis of primary investigation. These were then screened against selection criteria to identify pertinent clinical trials. RESULTS: Ninety-five clinical trials satisfied all inclusion criteria, with 55 (58%) trials specific to the DIPG diagnosis only. In terms of the most prevalent design features, 42 (44%) were phase I trials, with median expected start and completion years in 2011 (range, 1994-2020) and 2018 (range, 2005-2047), respectively. Median target number of patients to enroll was 38 (range, 1-1500), and the most common primary outcome was safety and toxicity (56%). There were 69 (73%) trials originating from the USA, with 49 (52%) of them being single institutional. Only 10 (11%) trials have reported results to date. CONCLUSIONS: To date, 95 clinical trials investigating DIPG with specific emphasis have been registered on ClinicalTrials.gov. There were only a small number of trials that had study results available, and they uniformly reported non-significant improvement to prognosis. Given the rarity and lethality of DIPG, which limits the accumulation of large cohorts, our results mandate the need for more robust, systematic clinical trial design to minimize redundancies and maximize yield in the future.
Authors: Jeremy Schwartzentruber; Andrey Korshunov; Xiao-Yang Liu; David T W Jones; Elke Pfaff; Karine Jacob; Dominik Sturm; Adam M Fontebasso; Dong-Anh Khuong Quang; Martje Tönjes; Volker Hovestadt; Steffen Albrecht; Marcel Kool; Andre Nantel; Carolin Konermann; Anders Lindroth; Natalie Jäger; Tobias Rausch; Marina Ryzhova; Jan O Korbel; Thomas Hielscher; Peter Hauser; Miklos Garami; Almos Klekner; Laszlo Bognar; Martin Ebinger; Martin U Schuhmann; Wolfram Scheurlen; Arnulf Pekrun; Michael C Frühwald; Wolfgang Roggendorf; Christoph Kramm; Matthias Dürken; Jeffrey Atkinson; Pierre Lepage; Alexandre Montpetit; Magdalena Zakrzewska; Krzystof Zakrzewski; Pawel P Liberski; Zhifeng Dong; Peter Siegel; Andreas E Kulozik; Marc Zapatka; Abhijit Guha; David Malkin; Jörg Felsberg; Guido Reifenberger; Andreas von Deimling; Koichi Ichimura; V Peter Collins; Hendrik Witt; Till Milde; Olaf Witt; Cindy Zhang; Pedro Castelo-Branco; Peter Lichter; Damien Faury; Uri Tabori; Christoph Plass; Jacek Majewski; Stefan M Pfister; Nada Jabado Journal: Nature Date: 2012-01-29 Impact factor: 49.962
Authors: Hiral P Fontanilla; Chelsea C Pinnix; Leena M Ketonen; Shiao Y Woo; Tribhawan S Vats; Michael E Rytting; Johannes E Wolff; Anita Mahajan Journal: Am J Clin Oncol Date: 2012-02 Impact factor: 2.339
Authors: A Aria Tzika; Loukas G Astrakas; Maria K Zarifi; David Zurakowski; Tina Young Poussaint; Liliana Goumnerova; Nancy J Tarbell; Peter McL Black Journal: Cancer Date: 2004-03-15 Impact factor: 6.860
Authors: Julian S Rechberger; Kendra A Porath; Liang Zhang; Cody L Nesvick; Randy S Schrecengost; Jann N Sarkaria; David J Daniels Journal: Pharmaceutics Date: 2022-04-24 Impact factor: 6.525
Authors: Stefaan W Van Gool; Jennifer Makalowski; Erin R Bonner; Oliver Feyen; Matthias P Domogalla; Lothar Prix; Volker Schirrmacher; Javad Nazarian; Wilfried Stuecker Journal: Medicines (Basel) Date: 2020-05-19
Authors: Liang Zhang; Cody L Nesvick; Charlie A Day; Jonghoon Choi; Victor M Lu; Timothy Peterson; Erica A Power; Jacob B Anderson; Feda H Hamdan; Paul A Decker; Renae Simons; John P Welby; Ruby Siada; Jizhi Ge; Tatiana Kaptzan; Steven A Johnsen; Edward H Hinchcliffe; David J Daniels Journal: Neuro Oncol Date: 2022-10-03 Impact factor: 13.029
Authors: Joshua D Bernstock; Samantha E Hoffman; Ari D Kappel; Pablo A Valdes; Walid Ibn Essayed; Neil V Klinger; Kyung-Don Kang; Stacie K Totsch; Hannah E Olsen; Charles W Schlappi; Katharina Filipski; Florian A Gessler; Lissa Baird; Mariella G Filbin; Rintaro Hashizume; Oren J Becher; Gregory K Friedman Journal: Oncoimmunology Date: 2022-09-26 Impact factor: 7.723